3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
1
Interventions
Dexamethasone
132
Lenalidomide
58
Bortezomib
56
Calcium Dobesilate
44
Melphalan
41
carfilzomib
38
pomalidomide
36
Cyclophosphamide
35
daratumumab
23
belantamab mafodotin
21
Peripheral Blood Stem Cell Transplantation
17
ixazomib
16
dexamethasone acetate
13
Filgrastim
13
Bendamustine Hydrochloride
13
fludarabine phosphate
12
fludarabine
12
dexamethasone 21-phosphate
12
Tacrolimus
12
auricularum
11
Whole-Body Irradiation
11
liposomal doxorubicin
10
iberdomide
10
Prednisone
10
venetoclax
9
selinexor
9
isatuximab
9
Mycophenolic Acid
9
pembrolizumab
8
Cyclosporine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Multiple Myeloma
×
melflufen
×
Clear all
NCT03481556
2022-12-19
ANCHOR
Oncopeptides AB
Phase 1/2
Terminated
56 enrolled
22 charts